Bush Jennifer
Bush Jennifer, COO, CLO, CO, reported an open-market or private sale at Artiva Biotherapeutics, Inc. involving 8391.000000 shares for an estimated $93605.80. Reported holdings after the transaction were 329529.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 03, 2026
- Filing date
- Sep 04, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 337,920 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
ARTV price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001193125-26-383621 Common Stock
- Transaction date
- Sep 03, 2026 Filed Sep 04, 2026, 08:03 PM · 1d delay
- Shares
- 8,391 sh $11.16 per share
- Estimated value
- -$93.6k Computed from shares × price
- Holdings after
- 329,529 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+10 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
COO, CLO, Compliance Officer
- F1
The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold…
- F2
The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0350 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder…
0 other transactions
0 recent txs